Business
EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics
EQT Life Sciences is pleased to announce that the LSP Health Economics Fund has exited Vivasure Medical Limited ("Vivasure" or the "Company"), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure, through a sale to Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes.
About this update from Eqt Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"EQT Life Sciences to exit portfolio company Vivasure Medical in sale to Haemonetics","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Vivasure's PerQseal® Elite system uses a special bioabsorbable patch to seal large access sites in arteries or veins from the inside","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"EQT supported Vivasure from its Series C investment in 2016 through clinical development and toward market approval","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":339,"olType":false},{"type":"text","content":"STOCKHOLM, Jan. 12, 2026 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP Health Economics Fund has exited Vivasure Medical Limited ("Vivasure" or the "Company"), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure, through a sale to Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes.","length":478,"tagName":"p"},{"type":"text","content":"Vivasure's PerQseal® Elite system uses a special bioabsorbable patch to seal large access sites in arteries or veins from the inside, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures. In 2025, Vivasure submitted a Premarket Approval application to the U.S. FDA for the PerQseal Elite system and received CE Mark approval in Europe for both arterial and venous use.","length":422,"tagName":"p"},{"type":"text","content":"EQT Life Sciences (formerly LSP) first invested in Vivasure in 2016 from the LSP Health Economics Fund, leading the Company's Series C funding round. From 2016 to 2025, EQT was represented on the Company's board by Partner Anne Portwich, providing active strategic support as Vivasure advanced its products through clinical studies and towards market approval.","length":368,"tagName":"p"},{"type":"text","content":"The acquisition includes an upfront cash payment of EUR 100 million, and up to an additional EUR 85 million in contingent consideration based on sales growth and the achievement of certain other milestones. The LSP Health Economics Fund is entitled to a portion of this amount, corresponding to its minority s...